Leadership

Dennis J. Carlo, Ph.D. Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotech research and development experience and is widely regarded as one of the “Founding Fathers” of the San Diego biotech industry. He was one of the original “Test Tube Cowboys” of Hybritech. He served as Vice President of Research and Development and Therapeutic Manufacturing at Hybritech Inc., which was acquired by Eli Lilly & Co in 1985. After the sale to Lilly, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberlin, founded The Immune Response Corporation, a public company, where he served in various capacities including Chief Scientific Officer, COO and President and Chief Executive Officer. He served as president of Telos Pharmaceuticals, a private biotechnology company, from 2003 to 2006. Dr. Carlo has extensive experience in the development of vaccines and biologics. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. At Hybritech, he managed a successful program to carry out research and development in the area of monoclonal antibody and cancer therapy. At The Immune Response Corporation, he established programs in Autoimmunity,Gene Therapy and HIV and led the product development in successful clinical trials. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology.

Robert O. Hopkins. Mr. Hopkins joined Adamis in April 2007 and has been Vice President, Finance and Chief Financial Officer since August 2007. From 2000 to 2004, he was an Executive Vice President and the Chief Financial Officer of Chatham Capital Corp. Mr. Hopkins served as Chief Financial Officer of Veritel Corp from 1999 and 2000, a biometric software company. He also served as Chief Operating Officer for Circle Trust Company from 2004 to 2005. From 2005 until Mr. Hopkins joined Adamis in 2007, he consulted for Acumen Enterpises providing analysis and business plans for the various projects. From 1997 to 1999, Mr. Hopkins was Senior Vice President for Finance for the Mariner Post-Acute Network. Among his previous medical-related experience, he has served as Assistant Administrator of Finance for Kindred Hospitals; President and Chief Executive Officer of Doctors Hospital of Hyde Park; and Vice President of Accounting for Cancer Treatment Centers of America. Mr. Hopkins received a B.S. degree in Finance from Indiana State University and an M.B.A. from Lake Forest Graduate School of Management.

David J. Marguglio. Mr. Marguglio is a co-founder of Adamis and has served as Senior Vice President of Corporate Development and Investor Relations since June 2006. From 1996 to 2006, he held various positions of Vice President with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which he successfully sold to a Fortune 100 company. Mr. Marguglio began his career as a financial analyst. He received a degree in finance and management from the Hankamer School of Business at Baylor University.

Thomas Moll, Ph.D. Dr. Moll has close to 20 years of experience in both academic and industrial preclinical research and development in the areas of inflammation, immunology and cancer biology. As part of his work, Dr. Moll has gained extensive experience in the generation, production and use of biologics, including protein/Fc chimeras, antibodies and gene therapeutics. After concluding his diploma studies in Biochemistry at the Biocenter, University of Basel, Switzerland, Dr. Moll received his doctorate degree in Genetics and Biochemistry “With Honours” from the University of Vienna, Austria. Subsequent to his work with Boehringer Ingelheim and Sandoz (now Novartis) in Vienna, Austria, Dr. Moll served as Assistant Professor at the University of Muenster, Germany, before joining Cardion AG, a privately held German biotech company. At Cardion, (then Cardiogene) Dr. Moll was initially in charge of the company’s preclinical cardiovascular gene therapy program, before taking over the responsibility for Cardion’s immunology programs as Vice President of Immunology. In this function he supervised the research and preclinical development of several protein/Fc fusion proteins, including CRB-15, an antagonist IL-15/Fc fusion protein. In 2003, Roche Pharmaceuticals licensed this protein for clinical development in various autoimmune disease indications. Before joining the Adamis management team, Dr. Moll was responsible for all research and development activities at Telos Pharmaceuticals. Dr. Moll serves as Editor of the Journal of Immune Based Therapies and has been a member of the European Society of Gene Therapy, the North American Vascular Biology Organization, the American Association of Immunologists, and the American Society of Transplantation.

Karen K. Daniels. Ms. Daniels joined Adamis in July 2009 as Vice President of Operations. She has over 30 years of experience in operational and engineering roles across diverse industries including: electronics, medical devices, contract manufacturing and pharmaceutical manufacturing. Prior to joining Adamis, Ms. Daniels served as President of Althea Technologies from 2007 to 2009. Althea Technologies is a contract manufacturer for the pharmaceutical industry. She also served as Sr. Director of operations and logistics for Vidacare, a medical device manufacturer from 2006 to 2007. Other roles have included President at Lambda Power 2003-2006, General Manager for Plexus Corporation and COO of Qtron which was sold to Plexus (1999-2003). Ms. Daniels has a BS degree from the University of Arizona.

Dennis J. Carlo, Ph.D. Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotech research and development experience and is widely regarded as one of the “Founding Fathers” of the San Diego biotech industry. He was one of the original “Test Tube Cowboys” of Hybritech. He served as Vice President of Research and Development and Therapeutic Manufacturing at Hybritech Inc., which was acquired by Eli Lilly & Co in 1985. After the sale to Lilly, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberlin, founded The Immune Response Corporation, a public company, where he served in various capacities including Chief Scientific Officer, COO and President and Chief Executive Officer. He served as president of Telos Pharmaceuticals, a private biotechnology company, from 2003 to 2006. Dr. Carlo has extensive experience in the development of vaccines and biologics. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. At Hybritech, he managed a successful program to carry out research and development in the area of monoclonal antibody and cancer therapy. At The Immune Response Corporation, he established programs in Autoimmunity, Gene Therapy and HIV and led the product development in successful clinical trials. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology.

David J. Marguglio. Mr. Marguglio is a co-founder of Adamis and has served as Senior Vice President of Corporate Development and Investor Relations since June 2006. From 1996 to 2006, he held various positions of Vice President with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which he successfully sold to a Fortune 100 company. Mr. Marguglio began his career as a financial analyst. He received a degree in finance and management from the Hankamer School of Business at Baylor University.

Tina S. Nova, Ph.D. Dr Nova currently serves as President and Chief Executive Officer of Genoptix, Inc. (NASDAQ:GXDX - News), a public life science company which recently announced its sale to Novartis. From 1994 to January 2000, Dr. Nova served as Chief Operating Officer and President of Nanogen, Inc., a provider of molecular diagnostic tests, where she was a co-founder. From 1992 to 1994, Dr. Nova served as Chief Operating Officer of Selective Genetics, a targeted therapy biotechnology company. She currently serves as a member of the Board of Directors of Arena Pharmaceuticals, Inc. a publicly held clinical-stage biopharmaceutical company. She also serves on the Board of Trustees of the University of San Diego and was a former life science sector representative to the Independent Citizen’s Oversight Committee overseeing the California Stem Cell Initiative (Proposition 71). Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.

Craig A. Johnson. Mr. Johnson has served as one of our directors since February 2011. Mr. Johnson currently serves as Chief Financial Officer of PURE Bioscience, Inc. Prior to joining PURE, in 2010 and 2011, he served as Senior Vice President and Chief Financial Officer of NoveDel Pharma Inc. From 2004 to 2010, Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. From 1994 to 2004, he was employed by MitoKor, Inc. and last held the position of Chief Financial Officer and Senior Vice President of Operations. Prior to joining MitoKor, Mr. Johnson served as a senior financial executive for several early-stage technology companies, and he also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson is currently a director of Ardea Biosciences, Inc., where he serves as the chairman of the audit committee. He received his B.B.A. in accounting from the University of Michigan and is a certified public accountant.

Kenneth M. Cohen. Mr. Cohen is an advisor to companies, entrepreneurs and investors in the life sciences area, and is currently chairman of Pier Pharmaceuticals, a privately held clinical stage biopharmaceutical company engaged in the treatment of sleep-related breathing disorders. He was a co-founder of publicly held Somaxon Pharmaceuticals and served as its President and Chief Executive Officer from August 2003 through December 2007 and continued as a director until June 2008. He has held positions as chief executive officer of Synbiotics Corporation, a diagnostics company, and has also held executive officer positions at Canji Incorporated, a human gene-therapy company which was acquired by Schering-Plough Corporation in February 1996, Argus Pharmaceuticals, Inc. and LifeCell Corporation. Mr. Cohen began his career at Eli Lilly and Company where, among many different responsibilities over 10 years, he directed business planning for the Medical Instrument Systems Division and managed the launch of Prozac. He received an A.B. in biology and chemistry from Dartmouth College and an M.B.A. from the Wharton School of The University of Pennsylvania.